Hepatitis B vaccination: a completed schedule ...enough to control HBV lifelong?

Milan, Italy, November 17-18, 2011

Thursday, November 17, 2011

Session 1 Introduction
Chair: Alessandro Zanetti, Pierre Van Damme

09.00 - 09.30

  • Welcome and opening
  • Introduction of the participants
  • Introduction of the VHPB: 1.6 Mb(.pdf) by Pierre Van Damme
  • Objectives of the meeting:
    • To review long-term efficacy of hepatitis B vaccine and field effectiveness of hepatitis B vaccination programmes;
    • To review recent data on immune memory induced by hepatitis B vaccine and the anamnestic response after a booster dose;
    • To examine the occurrence and impact of breakthrough infections;
    • To review data on potential impact of HBV mutants;
    • To evaluate the role of adjuvants in long-term protection;
    • To evaluate current hepatitis B booster vaccination recommendations;
    • To discuss current used definitions, standards and terminology.
  • Review of the meeting programme
  • Pre-meeting document KB (.pdf)

Session 2 HEPATITIS B VACCINE EFFICACY: Long-term immunogenicity/efficacy
Chair: Paolo Bonanni, Francoise Roudot-Thoraval

Immunogenicity after primary vaccination (follow-up studies)

High endemic region

09.30 – 09.50
Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in Thailand   1.2 Mb (.pdf)
Yong Poovorawan (Chulalongkorn University, Bangkok, Thailand)

Low/intermediate endemic region

09.50 – 10.10
Hepatitis B immune memory in children primed with hexavalent vaccines  375Kb (.pdf)
Alessandro Zanetti (Virology University of Milan, Italy)

10.10 – 10.30
30 year follow up study after Hepatitis B vaccination in Alaska.  636Kb (.pdf)
Brian McMahon (CDC and Alaska Native Medical Center, Alaska, USA)

10.30 – 10.45 Discussion

10.45 – 11.05 Coffee Break

Factors influencing long-term protection (age, vaccine schedule,vaccine composition…)

11.05 – 11.25
Influencing factors on long-term protection of hepatitis B after infant vaccination. 384 Kb (.pdf)
Marianne van der Sande (National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands)

11.25 – 11.55
Role of adjuvants on long term immunity. 2.8 Mb (.pdf)
Geert Leroux-Roels (Center for Vaccinology (CEVAC) – Ghent University and Hospital, Ghent, Belgium)

11.45 – 11.55 Discussion

Chair: Vana Papaevangelou , Koen Van Herck

11.55 – 12.15
Humoral and cellular immune responses after hepatitis B (booster)vaccination. How long will immune memory last? 604 Kb (.pdf)
Wolfgang Jilg  (Institute for Medical Microbiology and Hygiene,University of Regensburg, Germany)

12.15 – 12.35
Switched memory B cells maintain specific memory independently of serum antibodies. 3 Mb (.pdf)
Rita Carsetti (Research Center Ospedale Bambino Gesu, Roma, Italy)

12.35 – 12.55
55 Long-term persistence of T cell memory in Italian vaccinees. 636 Kb (.pdf)
Mario Clerici (Immunology, University of Milano, Italy)

12.55 – 14.00 Lunch

14.00 – 14.20
Impact of natural boostering on long-term protection against hepatitis B after newborn (HBsAg + mothers) vaccination.509 Kb (.pdf)
Ludek Roznovsky (Department of Infectious Diseases, University Hospital, Ostrava, Czech Republic)

14.20 – 14.40
Determination of immune memory to hepatitis B vaccination through early booster response in college students.
Jan Chyi-Feng (National Taiwan University Hospital, Taipei, Taiwan)

14.40 – 15.00
Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. 154 Kb (.pdf)
Brian McMahon (CDC And Alaska Native Medical Center, Alaska, USA)

15.00 – 15.10 Discussion

Chair: Mark Kane , Daniel Lavanchy

High endemic region

15.10 – 15.30
Gambia: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. 238 Kb (.pdf)
Hilton Whittle (London School of Hygiene and Tropical Medicine, London,UK)

15.30– 15.50
Thailand: Hepatitis B seroprevalence in Thailand: 15 years after hepatitis B vaccine integration into the national expanded programme on immunization. 1.6 Kb (.pdf)
Yong Poovorawan (Chulalongkorn University, Bangkok Thailand)

15.50 – 16.10 Coffee Break

Low/intermediate endemic region

16.10– 16.30
Spain: Epidemiology of acute hepatitis B nineteen years after the introduction of universal vaccination of preadolescents in Catalonia (Spain). 876 Kb (.pdf)
Angela Dominguez (Department of Public Health,University of Barcelona, Spain)

16.30– 16.50
Italy: Impact of universal vaccination programmes on the epidemiology of hepatitis B in Italy (SEIEVA results). 452 Kb (.pdf)
Alfonso Mele (Instituto Superiore di Sanita, Roma, Italy)

16.50– 17.10
Bulgaria: Impact of the universal newborn HBV vaccination programme: 20 years after. 152 Kb (.pdf)
Mira Kojouharova (National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria)

17.10– 17.30
USA: Impact of universal vaccination programme: surveillance for acute viral hepatitis - United States. 322 Kb (.pdf)
Trudy Murphy (CDC, USA)

17.30 – 17.45 Discussion

17.45 End of the Day

Friday, November 18, 2011

Chair: Daniel Shouval, Helène Norder

09.00 – 09.20
Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants.
Yen-Hsuan Ni (Children’s Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan)

09.20 – 09.40
Persistent and transient hepatitis B virus (HBV) infections in children born to HBV-infected mothers despite active and passive vaccination.
Marianne van der Sande for Susan Hahné (National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands)

09.40 – 10.00
Breakthrough HBV infections in vaccinated people: a ten years surveillance study in Italy. 252 Kb (.pdf)
Maria Elena Tosti (Instituto Superiore di Sanita, Roma, Italy)

10.00– 10.20
Phenotypic methods for investigating the impact of variation on HBsAg antigenicity.  361 Kb (.pdf)
Samreen Ijaz (Health Protection Agency, London, UK)

10.20 – 10.40 Discussion

10.40 – 11.00 Coffee break

Chair:Johannes Hallauer, Nedret Emiroglu

11.00 – 11.20
Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Basis for policy? 2.3Mb (.pdf)    Mathematical model (excel file)
Jamie Wilson (Department of Biological Sciences, University of Warwick, UK)

Country or regional policies

11.20– 11.30
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian policy. 448 Kb (.pdf)
Alessandro Zanetti (Department of Public Health, Microbiology, Virology University of Milan, Italy)

11.40– 12.00
Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies.
Yen-Hsuan Ni (Children’s Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan)

12.00– 12.20
Current CDC Hepatitis B immunization policy. Is there enough evidence for booster policy? 372 Kb (.pdf)
John Ward (CDC, USA)

Global Immunization policies

12.20 – 12.40
WHO booster policy –GRADE approach 873 Kb (.pdf)
Steven Wiersma (WHO, Genève, Switzerland)

12.40 – 12.55 Discussion

12.55– 14.30 Lunch

Session 7 Conclusions of the meeting
Chair: Steven Wiersma,

14.30 – 15.30
Presentation of the VHPB meeting conclusions 56 Kb(.pdf)
David FitzSimons

15.30 Close of the meeting